Aclasta patients get more insurance coverage

Novartis Korea said on March 11 that health insurance coverage for Aclasta (zoledronate 5 mg) has been expanded in patients (aged over 65 years) with previous hip and vertebral fracture.

Zoledronate has been approved as a once-yearly 5 mg infusion for treatment of osteoporosis and shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and imp...